TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$72.45
Market Cap
$11.36B
52W High
$72.69
52W Low
$43.07
ADV30
2,948,241
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
| Sep 2025 | 286,555,000 | 188,112,000 | 47,658,000 | 38,185,000 | 2,526,148,000 | 144,962,000 | 560,334,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$294,858,000
Investing CF
$-10,727,000
Financing CF
$-226,358,000
CapEx
$-25,260,000
Dividends Paid
$-49,819,000
Buybacks
$-100,081,000
EPS Diluted TTM
$0.69
As of
2026-08-30
Balance + Analyst (yfinance extras)
Retained Earnings
$1,145,192,000
Inventory
$201,175,000
Receivables
$214,562,000
ST Investments
$0
EBIT TTM
$156,826,000
Pretax Income TTM
$147,141,000
Interest Exp TTM
$9,685,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,215,038,976
EBITDA
$334,105,984
Free Cash Flow
$229,653,120
Enterprise Value
$11,333,339,136
Total Cash
$265,479,008
Total Debt
$289,087,008
Shares Out
156,818,238
Trailing EPS
$1.16
Book Value
$13.51
ROE
9.0%
ROA
6.7%
Div Yield
0.44%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,215,039,000 | 272,611,000 | 181,862,000 | 2,586,726,000 | 478,505,000 | 2,108,221,000 | 292,073,000 |
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | 1,918,808,000 | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | 2,068,850,000 | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | 1,966,516,000 | 254,393,000 |
TTM Snapshot
Revenues TTM
$1,210,812,000
NetIncome TTM
$109,563,000
OpCashFlow TTM
—
Assets (Latest)
$2,550,601,000
Forward EPS
$2.31
Max Pain — expiry 2026-10-16
max pain strike: $50.00 · spot: $72.46 · call oi: 18,432 · put oi: 453
Expected Move to 2026-10-16:
±$2.05
(2.83%) —
implied range
$70.41 –
$74.51
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | $10.50B | $9.91 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $12.47B | $109.84 | — |
| TWST | Twist Bioscience Corp | $10.08B | $152.05 | — |
| KRYS | Krystal Biotech, Inc. | $9.69B | $327.30 | — |
| PCVX | Vaxcyte, Inc. | $9.67B | $65.01 | — |
News headlines (Yahoo Finance, 1h cache)
1 Unpopular Stock That Should Get More Attention and 2 We Question
2026-10-09 14:43 · Yahoo
Bio-Techne opens GMP small molecule facility in Bristol, UK
2026-10-09 11:02 · Yahoo
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
2026-10-08 12:00 · Yahoo
2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off
2026-09-28 13:42 · Yahoo
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
2026-09-23 13:20 · Yahoo
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
2026-09-22 13:00 · Yahoo
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
2026-09-15 04:30 · Yahoo
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
2026-09-01 10:30 · Yahoo
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
2026-08-31 21:08 · Yahoo
Is Bio-Techne Stock Outperforming the Nasdaq?
2026-09-24 08:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.